Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.
Approval Alert | Adjuvant Durvalumab/Chemotherapy in Muscle-Invasive Bladder Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
3
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
4
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
5